Segment and Related Information (Tables)

9 Months Ended

Mar. 31, 2015

Segment Revenue and Operating Income (Loss)

Segment revenue and operating income (loss) were as follows during the periods presented:


(In thousands)	Molecular diagnostics		Pharmaceutical & clinical services			Research			Total
Three months ended March 31, 2015:
Revenue	$	172,978		7,007			—		$	179,985
Depreciation and amortization		5,207		566			626			6,399
Segment operating income (loss)		55,198		(1,147	)		(18,311	)		35,740

Three months ended March 31, 2014:
Revenue	$	176,191		6,733			—		$	182,924
Depreciation and amortization		2,506		471			502			3,479
Segment operating income (loss)		70,815		(73	)		(15,455	)		55,287

Nine months ended March 31, 2015:
Revenue	$	516,634		16,582			—		$	533,216
Depreciation and amortization		15,176		1,465			1,748			18,389
Segment operating income (loss)		159,299		(3,941	)		(57,356	)		98,002

Nine months ended March 31, 2014:
Revenue	$	565,335		24,115			—		$	589,450
Depreciation and amortization		5,335		1,462			1,494			8,291
Segment operating income (loss)		266,794		2,816			(48,422	)		221,188


	Three months ended March 31,						Nine months ended March 31,
(In thousands)	2015			2014			2015		2014
Total operating income for reportable segments	$	35,740		$	55,287		$	98,002	$	221,188
Interest income		124			2,498			265		5,190
Other		(298	)		(442	)		1,117		(1,066	)
Income tax provision		14,091			20,573			37,896		82,719

Net income	$	21,475		$	36,770		$	61,488	$	142,593

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details